Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0X7VB
|
||||
| Former ID |
DNCL001693
|
||||
| Drug Name |
MBX-102
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Gout [ICD9: 274.00274.1274.8274.9; ICD10:M10] | Phase 2/3 | [1] | ||
| Company |
Metabolex
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C19H17ClF3NO4
|
||||
| Canonical SMILES |
CC(=O)NCCOC(=O)C(C1=CC=C(C=C1)Cl)OC2=CC=CC(=C2)C(F)(F)F
|
||||
| InChI |
1S/C19H17ClF3NO4/c1-12(25)24-9-10-27-18(26)17(13-5-7-15(20)8-6-13)28-16-4-2-3-14(11-16)19(21,22)23/h2-8,11,17H,9-10H2,1H3,(H,24,25)/t17-/m1/s1
|
||||
| InChIKey |
BJBCSGQLZQGGIQ-QGZVFWFLSA-N
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | Peroxisome proliferator activated receptor gamma | Target Info | Agonist | [2] | |
| KEGG Pathway | PPAR signaling pathway | ||||
| AMPK signaling pathway | |||||
| Osteoclast differentiation | |||||
| Huntington's disease | |||||
| Pathways in cancer | |||||
| Transcriptional misregulation in cancer | |||||
| Thyroid cancer | |||||
| NetPath Pathway | IL1 Signaling Pathway | ||||
| TGF_beta_Receptor Signaling Pathway | |||||
| Leptin Signaling Pathway | |||||
| PANTHER Pathway | CCKR signaling map ST | ||||
| Pathway Interaction Database | Noncanonical Wnt signaling pathway | ||||
| Calcineurin-regulated NFAT-dependent transcription in lymphocytes | |||||
| Signaling events mediated by HDAC Class I | |||||
| RXR and RAR heterodimerization with other nuclear receptor | |||||
| Regulation of retinoblastoma protein | |||||
| Reactome | PPARA activates gene expression | ||||
| Transcriptional regulation of white adipocyte differentiation | |||||
| Nuclear Receptor transcription pathway | |||||
| WikiPathways | Wnt Signaling Pathway Netpath | ||||
| Nuclear Receptors in Lipid Metabolism and Toxicity | |||||
| Differentiation of white and brown adipocyte | |||||
| Regulation of Lipid Metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha) | |||||
| Transcriptional Regulation of White Adipocyte Differentiation | |||||
| Adipogenesis | |||||
| SREBP signalling | |||||
| Nuclear Receptors | |||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT00353587) Safety and Efficacy Study of Metaglidasen in Type 2 Diabetes in Patients Suboptimally Controlled on Insulin. U.S. National Institutes of Health. | ||||
| REF 2 | MBX-102/JNJ39659100, a novel peroxisome proliferator-activated receptor-ligand with weak transactivation activity retains antidiabetic properties in the absence of weight gain and edema. Mol Endocrinol. 2009 Jul;23(7):975-88. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.